Inactivated poliovirus vaccine: Past and present experience

Vaccine

Volumn 14, Issue 8, 1996, Pages 735-746

  Murdin, Andrew D ^a   Barreto, Luis ^a   Plotkin, Stanley ^b  

^a Connaught Laboratories Ltd ^*  (Canada)

^b Pasteur Merieux Serums et Vaccins   (France)

Author keywords

Inactivated poliovirus vaccine; Poliovirus; Vaccination strategies

Indexed keywords

INACTIVATED VIRUS VACCINE; POLIOMYELITIS VACCINE;

HEALTH CARE POLICY; HISTORY OF MEDICINE; HUMAN; INCIDENCE; INFECTION CONTROL; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0030175812     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00211-I     Document Type: Review

References (118)

1. 1 Salk, J. and Salk, D. Control of influenza and poliomyelitis with killed virus vaccines. Science 1977, 195, 834-847
2. 2 Horaud, F. and Albert, B. Sabin and the development of oral poliovaccine. Biologicals 1993, 21, 311-316
3. 3 Sabin, A.B. Present position of immunization against poliomyelitis with live virus vaccines. Br. Med. J. 1959, 3, 663-680
4. 4 Sabin, A.B. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis. 1985, 151, 420-436
5. 5 Nkowane, B.M., Wassilak, S.G.F., Orenstein, W.A. et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. J. Am. Med. Assoc. 1987, 257, 1335-1340
6. 6 Salk, D. Eradication of poliomyelitis in the United States. I. Live virus vaccine-associated and wild poliovirus disease. Rev. Infect. Dis. 1980, 2, 228-242
7. 7 Henderson, D.A., Witte, J.J., Morris, L. and Langmuir, A.D. Paralytic disease associted with oral polio vaccines. J. Am. Med. Assoc. 1964, 190, 153-160
8. 8 Prevots, D.R., Sutter, R.W., Strebel, P.M., Weibel, R.E. and Cochi, S.L. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Arch. Ped. Adoles. Med. 1994, 20, 479-485
9. 9 Report of the National Certification Commission on Polio Eradication in Canada, August 1994
10. 10 CDC. Poliomyelitis - United States, 1975-1984. Morbid. Mortal. Wkly Rep. 1986, 35(11), 180-182
11. 11 Strebel, P.M., Ion-Nedelcu, N., Baughman, A.L., Sutter, R.W. and Cochi, S.L. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine - a risk factor for vaccine-associated paralytic poliomyelitis. N. Engl. J. Med. 1995, 332, 500-506
12. 12 Stickle, G. Observed and expected poliomyelitis in the United States, 1958-1961. Am. J. Publ. Hlth 1964, 54, 1222-1229
13. 13 Sabin, A.B. Reflections on the qualitative and quantitative aspects of neurovirulence of different polioviruses. Biologicals 1993, 21, 317-320
14. 14 Strebel, P.M., Sutter, R.W., Cochi, S.L. et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 1992, 14, 568-579
15. 15 Vidor, E., Caudrelier, P. and Plotkin, S. The place of DTP/elPV vaccine in routine pediatric vaccination. Rev. Med. Virol. 1994, 4, 261-277
16. 16 Böttiger, M. Experiences of vaccination with inactivated poliovirus vaccine in Sweden. Dev. Biol. Stand. 1981, 47, 227-232
17. 17 Böttiger, M. and Fagraeus, A. Polio vaccination in Sweden. Rev. Infect. Dis. 1980, 2, 274-276
18. 18 Böttiger, M. and Larsson, B. Swedish inactivated polio vaccine: laboratory standardization and clinical experience over a 30-year period. Biologicals 1992, 20, 267-275
19. 19 Böttiger, M. The elimination of polio in the Scandinavian countries. Publ. Hlth Rev. 1993/94, 21, 27-33
20. 20 Böttiger, M., Mellin, P., Romanus, V., Söderström, H., Wesslen, T. and von Zeipel, G. Epidemiological events surrounding a paralytic case of poliomyelitis in Sweden. Bull. WHO 1979, 57, 99-103
21. 21 Hovi, T., Huovilainen, A., Kuronen, T. et al. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1986, 1427-1432
22. 22 Böttiger, M. Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 1990, 8, 443-445
23. 23 Mellander, L., Böttiger, M., Hanson, L.A., Taranger, J. and Carlsson, B. Avidity and titers of the antibody response to two inactivated poliovirus vaccines with different antigen content. Acta Pædiatr. 1993, 82, 552-556
24. 24 Lapinleimu, K. and Stenvik, M. Experiences with polio vaccination and herd immunity in Finland. Dev. Biol. Stand. 1981, 47, 241-246
25. 25 Lapinleimu, K. and Stenvik, M. The efficacy of polio vaccination in Finland. Dev. Biol. Stand. 1978, 41, 137-139
26. 26 Lapinleimu, K. Elimination of poliomyelitis in Finland. Rev. Infect. Dis. 1984, 6 (Suppl. 2), S457-S460
27. 27 Magrath, D.I., Evans, D.M.A., Ferguson, M. et al. Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population. J. Gen. Virol. 1986, 67, 899-905
28. 28 Wimmer, E., Hellen, C.U.T. and Cao, X. Genetics of poliovirus. A. Rev. Genet. 1993, 27, 353-436
29. 29 Abraham, R. and Ogra, P.L. Mucosal microenvironment and mucosal response. Am. J. Trop. Med. Hyg. 1994, 505, 3-9
30. 30 Roivainen, M. and Hovi, T. Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine. J. Virol. 1987, 61, 3749-3753
31. 31 Roivainen, M., Huoviuainen, A. and Hovi, T. Antigenic modification of polioviruses by host proteolytic enzymes. Arch. Virol. 1990, 111, 115-125
32. 32 Icenogle, J.P., Minor, P.D., Ferguson, M. and Hogle, J.M. Modulation of humoral response to a 12-amino-acid site on the poliovirus virion. J. Virol. 1986, 60, 297-301
33. 33 Roivainen, M., Montagnon, B., Chalumeau, H., Murray, M., Wimmer, E. and Hovi, T. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice. J. Virol. 1990, 64, 559-562
34. 34 Zhaori, G., Sun, M., Faden, H.S. and Ogra, P.L. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J. Infect. Dis. 1989, 159, 1018-1024
35. 35 Böttiger, M. Neutralizing capacity of poliovirus type 3 antibodies tested against 5 different intratypic variants of polivirus type 3. Arch. ges. Virusforsch. 1971, 35, 251-255
36. 36 Hofman, B. Poliomyelitis in the Netherlands 1958-69: the influence of a vaccination programme with inactivated poliovaccine. Bull. WHO 1972, 46, 735-745
37. 37 Hofman, B. Poliomyelitis in the Netherlands before and after vaccination with inactivated poliovaccine. J. Hyg. (Camb.) 1967, 65, 547-557
38. 38 Salk, J., van Wezel, A.L., Stoeckel, P. et al. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. Dev. Biol. Stand. 1981, 47, 181-198
39. 39 van Wezel, A.L., van Steenis, G., van der Marel, P. and Osterhaus, A.D.M.E. Inactivated poliovirus vaccine: current production methods and new developments. Rev. Infect. Dis. 1984, 6Suppl. 2, S335-S340
40. 40 Salk, D. Induction of long-term immunity to paralytic poliomyelitis by use of non-infectious vaccine. Lancet 1984, 1317-1321
41. 41 Hofman, B. Note on vaccination in the Netherlands. Symp. Series Immunobiol. Stand. 1973, 22, 357-359
42. 42 van Wijngaarden, U.K. and van Loon, A.M. The polio epidemic in the Netherlands, 1992/1993. Publ. Hlth Rev. 1993/94, 21, 107-116
43. 43 Bijkerk, H. Poliomyelitis in the Netherlands. Dev. Biol. Stand. 1981, 47, 233-240
44. 44 Bijkerk, H. Poliomyelitis epidemic in the Netherlands, 1978. Dev. Biol. Stand. 1979, 43, 195-206
45. 45 Oostvogel, R.M., Wijngaarden, J.K., Avoort, H.G.A.M. et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93. Lancet 1994, 344, 665-670
46. 46 Furesz, J. Poliomyelitis outbreaks in the Netherlands and Canada. CMA J. 1979, 120, 905-906
47. 47 Epidemiological Notes and Reports: follow-up on poliomyelitis - United States, Canada, Netherlands. Morbid. Mortal. Wkly Rep. 1979, 28, 345-346
48. 48 Lack of Evidence for Wild Poliovirus Circulation - United States, 1993. Morbid. Mortal. Wkly Rep. 1995, 43, 957-959
49. 49 Epidemiological Notes and Reports: isolation of wild polivirus type 3 among members of a religious community objecting to vaccination - Alberta, Canada, 1993. Morbid. Mortal. Wkly Rep. 1993, 42(17), 337-339
50. 50 Wild poliovirus isolated in Alberta, 1993. CCDR 1993, 19(8), 57-58
51. 51 Schaap, G.J.P., Bijkerk, H., Coutinho, R.A., Kapsenberg, J.G. and van Wezel, A.L. The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Prog. Med. Virol. 1984, 29, 124-140
52. 52 Salk, J.E. Antigenic potency of poliomyelitis vaccine. J. Am. Med. Assoc. 1956, 162, 1451-1459
53. 53 Salk, J.E. Considerations in the preparation and use of poliomyelitis virus vaccine. J. Am. Med. Assoc. 1955, 158, 1239-1248
54. 54 Salk, J.E. How many injections of poliomyelitis vaccine for effective and durable immunity? J. Am. Med. Assoc. 1958, 167, 1-7
55. 55 Salk, J.E. Persistence of immunity after administration of formalin-treated poliovirus vaccine. Lancet 1960, 715-723
56. 56 Salk, D. Eradication of poliomyelitis in the United States. II. experience with killed poliovirus vaccine. Rev. Infect. Dis. 1980, 2, 243-257
57. 57 Chin, T.D.Y. and Marine, W.M. The changing pattern of poliomyelitis observed in two urban epidemics. Publ. Hlth Rep. 1961, 76, 553-563
58. 58 Nathanson, N. and Langmuir, A.D. Poliomyelitis following formaldehyde-inactivated poliovirus vaccinaton in the United States during the spring of 1955. Am. J. Hyg. 1963, 78, 16-28
59. 59 Duchene, M., Peetermans, J., D'Hondt, E., Harford, N., Fabry, L. and Stephenne, J. Production of poliovirus vaccines: past, present, and future. Viral Immun. 1990, 3, 243-272
60. 60 Food and Drug Administration, HHS. Poliovirus vaccine inactivated, 630.1-630.5. 21 CFR Ch. I (4-1-93):83-87. Washington DC, USA
61. 61 Government of Canada. Poliomyelitis vaccine. The Food and Drugs Act and Regulations; p. 100, August 5, 1982 (R) and p. 100A, 24, July 1985. Ottawa, Canada
62. 62 Gudnadóttir, M. Experience of vaccination with inactivated poliomyelitis vaccines in Iceland. Dev. Biol. Stand. 1981, 47, 257-259
63. 63 Rudler, J. and Despert, F. Vaccination contre la poliomyelite. Revue Méd. Tours 1979, 13, 386-390
64. 64 Martin, R., Roger, F., Damas, J.P. and Roger, A. Deux ans et demi de vaccination antipoliomyélitique (vaccin Lépine) a l'hopital de l'Institut Pasteur. Résultats immunologiques. Importance de l'injection de rappel. Ann. Inst. Pasteur 1959, 97, 757-779
65. 65 Montagnon, B.J., Fanget, B. and Nicolas, A.J. The large-scale cultivation of vero cells in micro-carrier culture for virus vaccine production preliminary results for killed poliovirus vaccine. Dev. Biol. Stand. 1981, 47, 55-64
66. 66 Malvy, D.J.M. and Drucker, J. Elimination of poliomyelitis in France: epidemiology and vaccine status. Publ. Hlth Rev. 1993/94, 21, 41-49
67. 67 Varughese, P.V., Carter, A.O., Acres, S.E. and Furesz, J. Eradication of indigenous poliomyelitis in Canada: impact of immunization strategies. Can. J. Publ. Hlth 1989, 80, 363-368
68. 68 Furesz, J., Armstrong, R.E., Contreras, G. and Wachmann, B. Genetic characterization of poliovirus isolates in Canada, 1962-1981. Rev. Infect. Dis. 1984, 6Suppl. 2, S528-S534
69. 69 Furesz, J., Contreras, G., Acres, S.E. and Varughese, P. Strategies for the control of poliomyelitis in Canada, 1976-1987. National Academy of Sciences, Institute of Medicine Conference on Poliomyelitis Vaccines: Re-evaluating Policy Options. 21-22 January 1988, Washington DC
70. 70 Evaluation of Canadian poliovirus-related cases. Can. Dis. Wkly Rep. 1989, 15(37), 185-188
71. 71 Community surveillance for wild poliovirus in Ontario, 1993. Can. Communicable Dis. Rep. 1994, 20, 214-216
72. 72 Fox, J.P. Modes of action of poliovirus vaccines and relation to resulting immunity. Rev. Infect. Dis. 1984, 6Suppl. 2, S352-S355
73. 73 McBean, A.M. and Modlin, J.F. Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States. Ped. Infect. Dis. J. 1987, 6, 881-887
74. 74 Nightingale, E.O. Recommendations for a National Policy on Poliomyelitis Vaccination. N. Engl. J. Med. 1977, 297, 249-253
75. 75 Melnick, J.L. Advantages and disadvantages of killed and live poliomyelitis vaccines. Bull. WHO 1978, 56, 21-38
76. 76 Hinman, A.R., Koplan, J.P., Orenstein, W.A., Brink, E.W. and Nkowane, B.M. Live or inactivated poliomyelitis vaccine: an analysis of benefits and risks. Am. J. Publ. Hlth 1988, 78, 291-295
77. 77 Krugman, R.D., Hardy, G.E.Jr, Sellers, C. et al. Antibody persistence after primary immunization with trivalent oral poliovirus vaccine. Pediatrics 1977, 60, 80-82
78. 78 Nishio, O., Ishihara, Y., Sakae, K. et al. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. J. Biol. Standard. 1984, 12, 1-10
79. 79 Svennerholm, A.-M., Hanson, L.A., Holmgren, J. et al. Antibody response to live and killed poliovirus vaccines in the milk of Pakistani and Swedish women. J. Infect. Dis. 1981, 143, 707-711
80. 80 Zaman, S., Carlsson, B., Jalil, F. et al. Comparison of serum and salivary antibodies in children vaccinated with oral live or parenteral inactivated poliovirus vaccines of different antigen concentrations. Acta Paed. Scand. 1991, 80, 1166-1173
81. 81 Carlsson, B., Zaman, S., Mellander, L., Jalil, F. and Hanson, L.A. Secretory and serum immunoglobulin class-specific antibodies to poliovirus after vaccination. J. Infect. Dis. 1985, 152, 1238-1244
82. 82 Faden, H., Modlin, J.F., Thoms, M.L., McBean, A.M., Ferdon, M.B. and Ogra, P.L. Comparative evaluation of Immunizaton with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J. Infect. Dis. 1990, 162, 1291-1297
83. 83 Onorato, I.M., Modlin, J.F., McBean, A.M., Thoms, M.L., Losonsky, G.A. and Bernier, R.H. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J. Infect. Dis. 1991, 163, 1-6
84. 84 Zhaori, G., Sun, M. and Ogra, P.L. Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines. J. Infect. Dis. 1988, 158, 160-165
85. 85 Adenyi-Jones, S.C.A., Faden, H., Ferdon, M.B., Kwong, M.S. and Ogra, P.L. Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in permature and term infants. J. Fed. 1991, 120, 686-689
86. 86 Ogra, P.L. Mucosal immune response to poliovirus vaccines in childhood. Rev. Infect. Dis. 1984, 6Suppl. 2, S361-S368
87. 87 Ogra, P.L., Karzon, D.T., Righthand, F. and MacGillivray, M. Immunoglobulin response inserum and secretions after immunization with live and inactivated poliovaccine and natural infection. N. Engl. J. Med. 1968, 279, 893-900
88. 88 Dunn, G., Begg, N.T., Cammack, N. and Minor, P.D. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J. Med. Virol. 1990, 32, 92-95
89. 89 Marine, W.M., Chin, T.D.Y. and Gravelle, C.R. Limitation of fecal and pharyngeal poliovirus excretion in salk-vaccinated children. Am. J. Hyg. 1962, 76, 173-195
90. 90 Salk, D. Herd effect and virus eradication with us of killed poliovirus vaccine. Dev. Biol. Stand. 1981, 47, 247-255
91. 91 Dick, G.W.A., Dane, D.S., McAlister, J., Briggs, M. and Nelson, R. Vaccination against poliomyelitis with live virus vaccines. Br. Med. J. 1961, 2, 266-269
92. 92 Glezen, W.P., McCollough, R.H., Lamb, G.A. and Chin, T.D.Y. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1,2 and 3 following the feeding of trivalent attenuated poliovirus vaccine. Am. J. Epidemiol. 1969, 90, 146-156
93. 93 Modlin, J.F., Onorato, I.M., McBean, A.M. et al. The humoral immune response to type 1 oral poliovirus vaccine in children previously immunized with enhanced potency inactivated poliovirus vaccine in live oral poliovirus vaccine. Am. J. Dis. Control 1990, 144, 480-484
94. 94 Ramsay, M.E., Begg, N.T., Gandhi, J. and Brown, D. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Ped. Infect. Dis. J. 1994, 13, 1117-1121
95. 95 Murdin, A. and Thipphawong, J. Poliovirus vaccination schedules and reversion to virulence. J. Infect. Dis. 1992, 166, 935-936
96. 96 von Magnus, H. and Petersen, I. Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev. Infect. Dis. 1984, 6Suppl. 2, S471-S474
97. 97 Pedersen, I. and Rønne, T. Control of poliomyelitis with inactivated and oral vaccines. Presented at the 4th European Meeting of National Programme Managers on the Expanded Programme of Immunization, St Vincent, Val d'Aosta, Italy, 1991
98. 98 Tulchinsky, T.H. Combined OPV and IPV program in control of poliomyelitis in two endemic areas - a potential tool in the struggle to eradicate poliomyelitis. Publ. Hlth Rev. 1993/94, 21, 153-156
99. 99 Swartz, T.A. and Handsher, R. Israel in the elimination phase of poliomyelitis - achievements and remaining problems. Publ. Hlth Rev. 1993/94, 21, 99-106
100. 100 Tulchinsky, T., Abed, Y., Shaheen, S. et al. A ten-year experience in control of poliomyelitis through a combination of live and killed vaccines in two developing areas. Am. J. Publ. Hlth 1989, 79, 1648-1652
101. 101 Lasch, E.E., Abde, Y., Abdulla, K. et al. Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev. Infect. Dis. 1984, 6Suppl. 2, S467-S470
102. 102 Swartz, T.A., Ben-Porath, E., Kanaaneh, H., Leitner, L. and Goldblum, N. Comparison of inactivated poliovirus vaccine and oral poliovirus vaccine program in Israel. Rev. Infect. Dis. 1984, 6Suppl. 2, S556-S561
103. 103 Green, M.S., Slater, P.E. and Danon, Y. Analysis of historical epidemiological data to guide intervention policy in the face of an infectious disease outbreak: poliomyelitis in Israel in 1988. Int. J. Epidemiol. 1991, 20, 284-289
104. 104 Slater, P.E., Orenstein, W.A., Morag, A. et al. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 1990, 335, 1192-1198
105. 105 Minor, P.D. The molecular biology of poliovaccines. J. Gen. Virol. 1992, 73, 3065-3077
106. 106 Plotkin, S. Current issues in evaluating the efficacy of oral poliovirus vaccine and inactivated poliovirus vaccine immunization. Ped. Infect. Dis. J. 1991, 10, 979-981
107. 107 Faden, H. Poliovirus vaccination: a trilogy. J. Infect. Dis. 1993, 168, 25-28
108. 108 Abraham, R., Minor, P., Dunn, G., Modlin, J. and Ogra, P.L. Shedding a virulent poliovirus revendants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J. Infect. Dis. 1993, 168, 1105-1109
109. 109 Ogra, P.L., Faden, H.S., Abraham, R., Duffy, L.C., Sun, M. and Minor, P.D. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J. Infect. Dis. 1991, 164, 191-194
110. 110 Minutes of meeting, Advisory Committee on Immunization Practices, 12-13 February 1992 (Atlanta). Centers for Disease Control, Atlanta 1992
111. 111 Minutes of meeting, Advisory Committee on Immunization Practices, 23-24 February 1994 (Atlanta). Centers for Disease Control, Atlanta 1994
112. 112 Minor, P.D. and Dunn, G. The effect of sequences in the 5′ non-coding region of the replication of polioviruses in the human gut. J. Gen. Virol. 1988, 69, 1091-1096
113. 113 Tatem, J.M., Weeks-Levy, C., Mento, S.J. et al. Oral poliovirus vaccine in the United States: molecular characterization of sabin type 3 after replication in the gut of vaccines. J. Med. Virol. 1991, 35, 101-109
114. 114 Macadam, A.J., Arnold, C., Howlett, J. et al. Reversion of the attenuated and temperature-sensitive phenotypes of the sabin type 3 strain of poliovirus in vaccines. Virology 1989, 172, 408-414
115. 115 Evans, D.M.A., Dunn, G., Minor, P.D. et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 1985, 314, 548-550
116. 116 Chumakov, K.M., Powers, L.B., Noonan, K.E., Roninson, I.B. and Levenbook, I.S. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc. Natl Acad. Sci. USA 1991, 88, 199-203
117. 117 Böttiger, M. and Herrstrom, E. Isolation of polioviruses from sewage and their characteristics; experience over two decades in Sweden. Scand. J. Infect. Dis. 1992, 24, 151-155
118. 118 Ghendon, Y. and Robertson, S.E. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull. WHO 1994, 72, 973-983